Our study provides evidence that genetic inhibition of mPTP exacerbates RyR2 dysfunction in CPVT by increasing activation of the CaMKII pathway and subsequent hyperphosphorylation of RyR2. The gene discussed is CAMK2G; the disease is catecholaminergic polymorphic ventricular tachycardia.